Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Health to Present at Goldman Sachs 40th Annual Global Healthcare Conference
WALTHAM, Mass. , June 04, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona , Chief Financial Officer and Joe Kelly , Senior Vice President of Sales and Marketing, will present a corporate update at the Goldman Sachs 40th Annual Global Healthcare
View HTML
Toggle Summary Radius Health to Present at Bank of America Merrill Lynch Health Care Conference 2019
WALTHAM, Mass. , May 10, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Pepe Carmona , Chief Financial Officer and Joe Kelly , Senior Vice President of Sales and Marketing, will present a corporate update at the Bank of America Merrill Lynch Health Care Conference
View HTML
Toggle Summary Radius Health Announces First Quarter 2019 Operating Results
TYMLOS® U.S. net sales were $29.8 million in the first quarter of 201 9 doubling over the first quarter of 2018. TYMLOS continued increasing its share in the U.S. anabolic osteoporosis market capturing an average of 30% total market share and 42% share in new patients in the first quarter of 2019.
View HTML
Toggle Summary Radius Health to Announce First Quarter 2019 Financial Results, Host Conference Call and Live Webcast on Wednesday, May 8, 2019
WALTHAM, Mass. , April 23, 2019 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter 2019 financial results on Wednesday, May 8, 2019 . The Company will host a conference call and live audio webcast at 8:00 a.m.
View HTML
Toggle Summary Radius Health to Present Two Posters at AACE 2019 Annual Meeting
WALTHAM, Mass. , April 17, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it
View HTML
Toggle Summary Radius Health Presents Analysis from Phase 3 ACTIVE Trial and Data from Preclinical Studies for TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting
-Post-hoc analysis suggests abaloparatide may be useful in the treatment of women with postmenopausal osteoporosis and concurrent osteoarthritis, at high risk for fracture- -Preclinical studies provide explanations for the net bone gain observed in the Phase 3 ACTIVE trial in abaloparatide-treated
View HTML
Toggle Summary Radius Health to Present Data on TYMLOS® (abaloparatide) Injection at ENDO 2019 Annual Meeting
WALTHAM, Mass. , March 18, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology, today announced it
View HTML
Toggle Summary Radius Health to Present at Cowen 39th Annual Healthcare Conference
WALTHAM, Mass. , March 11, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President and CEO of the Company, will present a corporate update at the Cowen 39 th Annual Healthcare Conference on Wednesday, March 13, 2019 .
View HTML
Toggle Summary Radius Health to Participate in 2019 Credit Suisse Global Healthcare Conference
WALTHAM, Mass. , March 01, 2019 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Company management will be attending and participating in the 2019 Credit Suisse Global Healthcare Conference in London on Tuesday, March 5, 2019 and hosting one-on-one meetings with
View HTML
Toggle Summary Radius Health Announces Fourth Quarter and Full-Year 2018 Operating Results
TYMLOS® U.S. net sales continued to increase, reaching $34.4 million in the fourth quarter of 2018  and totaling $99.2 million for full-year 2018, exceeding the Company’s guidance of $95-98 million . Elacestrant’s Phase 3 study was initiated at the end of 2018 and is open for enrollment.
View HTML